id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2020-E-2362-0010,FDA,FDA-2020-E-2362,Notice of Final Determination and Requirement for Election,Other,Letter(s),2024-07-31T04:00:00Z,2024,7,2024-07-31T04:00:00Z,,2024-07-31T12:05:32Z,,0,0,0900006486605ec9
FDA-2020-E-2362-0009,FDA,FDA-2020-E-2362,Letter from FDA CDER to U S Patent and Trademark Office,Other,Letter(s),2023-07-13T04:00:00Z,2023,7,2023-07-13T04:00:00Z,,2023-07-13T16:49:20Z,,0,0,0900006485ca2171
FDA-2020-E-2362-0008,FDA,FDA-2020-E-2362,Determination of Regulatory Review Period for Purposes of Patent Extension; ENSPRYNG; Correction,Notice,Correction,2023-05-24T04:00:00Z,2023,5,2023-05-24T04:00:00Z,,2023-05-24T13:13:36Z,2023-10979,0,0,0900006485a47732
FDA-2020-E-2362-0007,FDA,FDA-2020-E-2362,"Response Letter from FDA CDER to Fish & Richardson, P.C.",Other,Letter(s),2023-05-16T04:00:00Z,2023,5,2023-05-16T04:00:00Z,,2023-05-16T14:26:54Z,,0,0,0900006485a0db44
FDA-2020-E-2362-0006,FDA,FDA-2020-E-2362,Request for Revision of Determination of Regulatory Review Period for Purposes of Patent Extension; ENSPRYNG,Other,Petition(s),2022-09-09T04:00:00Z,2022,9,2022-09-09T04:00:00Z,,2022-09-09T13:47:27Z,,0,0,09000064852cc47d
FDA-2020-E-2362-0005,FDA,FDA-2020-E-2362,Determination of Regulatory Review Period for Purposes of Patent Extension; ENSPRYNG,Notice,Determinations,2022-07-13T04:00:00Z,2022,7,2022-07-13T04:00:00Z,2022-09-13T03:59:59Z,2023-05-24T13:13:22Z,2022-14930,0,0,09000064851c6d73
FDA-2020-E-2362-0004,FDA,FDA-2020-E-2362,Letter from FDA CDER to U S Patent and Trademark Office,Other,Letter(s),2022-06-14T04:00:00Z,2022,6,2022-06-14T04:00:00Z,,2022-06-14T17:42:37Z,,0,0,0900006485162ecf
FDA-2020-E-2362-0003,FDA,FDA-2020-E-2362,Patent Term Extension Letter from FDA CDER to Honorable Drew Hirshfeld,Other,Extension of Time,2021-03-01T05:00:00Z,2021,3,2021-03-01T05:00:00Z,,2021-03-01T18:56:03Z,,0,0,0900006484a585bb
FDA-2020-E-2362-0001,FDA,FDA-2020-E-2362,Letter from U S Patent and Trademark Office,Other,Letter(s),2020-12-31T05:00:00Z,2020,12,2020-12-31T05:00:00Z,,2020-12-31T14:39:30Z,,0,0,09000064849d615f
FDA-2020-E-2362-0002,FDA,FDA-2020-E-2362,"Patent Term Extension Application for ENSPRYNG® Patent No 10,022,319",Other,Application,2020-12-31T05:00:00Z,2020,12,2020-12-31T05:00:00Z,,2020-12-31T14:40:22Z,,0,0,09000064849d6366